Executive Director, DNDi and DNDi Board Permanent Invitee
Dr Bernard Pécoul has led the Drugs for Neglected Diseases initiative (DNDi) since its foundation in 2003. Under his guidance, DNDi – a not-for-profit research and development organization – with hundreds of public and private partners, has delivered nine new treatments for six deadly diseases. It has developed a robust portfolio of projects spanning from discovery to implementation for sleeping sickness, leishmaniasis, Chagas disease, filaria, mycetoma, HIV, hepatitis C, and COVID-19.
DNDi aims to deliver 15-18 additional treatments by 2028, for a total of 25 new treatments in its first 25 years. The initiative, through its R&D work, also builds capacity in disease endemic countries through research platforms and technology transfers and advocates for greater public leadership to sustainably address the health needs of neglected patients.
Prior to DNDi, Dr Pécoul was Director of the Médecins Sans Frontières (MSF) Campaign for Access to Essential Medicines from 1998 to 2003, a position he took on after that of Executive Director of MSF-France. While working with MSF, Dr Pécoul carried out field missions in Africa, Latin America, and Asia. In 1988, he co-founded Epicentre, an MSF-affiliated NGO specialized in epidemiology.
After obtaining his medical degree at the University of Clermont-Ferrand, France, Dr Pécoul earned a master’s degree in public health at Tulane University, USA. In 2012, he was awarded an honorary Doctor of Laws Degree by the University of Dundee, UK. In 2020, Dr Pécoul was awarded the Prince Mahidol Award in the field of public health by the Prince Mahidol Award Foundation, Thailand.
Dr Pécoul is member of the Joint Coordination Board of the Special Programme for Tropical Disease Research (WHO/TDR) and a former board member of UNITAID’s Medicines Patent Pool.
Get our latest news, personal stories, research articles, and job opportunities.